Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer.
Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.
Pancreas Center, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA. mtempero@medicine.ucsf.edu
Margaret A
MA
Tempero
David
D
Klimstra
Jordan
J
Berlin
Tony
T
Hollingsworth
Paula
P
Kim
Nipun
N
Merchant
Malcolm
M
Moore
Doug
D
Pleskow
Andrea
A
Wang-Gillam
Andrew M
AM
Lowy
D018070:Biological Specimen Banks; D014408:Biomarkers, Tumor; D021441:Carcinoma, Pancreatic Ductal / Q000175:diagnosis*; D002986:Clinical Trials as Topic; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis*
D014408:Biomarkers, Tumor